Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Albiglutide Thorough ECG Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 94
- Registration Number
- NCT01406262
A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01398293
Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- University College, London
- Target Recruit Count
- 200
- Registration Number
- NCT01398072
- Locations
- 🇬🇧
Academic Unit of Respiratory Medicine, Royal Free Hospital, London, United Kingdom
Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 546
- Registration Number
- NCT01363323
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
- Conditions
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01359618
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Pharmacokinetics and Safety of Moxifloxacin
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 9
- Registration Number
- NCT01329250
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT01327066
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT01325415
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Treatment of Mycobacterium Xenopi Pulmonary Infection
- Conditions
- Interventions
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 92
- Registration Number
- NCT01298336
- Locations
- 🇫🇷
CH Béthune, Béthune, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷CH Abbeville, Abbeville, France
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT01297062
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.